February 16, 2010 (FinancialWire) — Hemispherx Biopharma, Inc. (NYSE AMEX: HEB)  said the board of directors of Hemispherx Biopharma, Inc. has approved the recommendations of the Compensation Committee to award bonuses to officers and key executives for performance in relation to their attainment of 2009 of company-wide goals as well at their achievements in individual goals and responsibilities.

The Compensation Committee and board of directors reviewed the individual achievements of each bonus eligible individual, along with their contribution towards meeting corporate goals established in May 2009, and determined that bonuses were justifiable based on significant progress made in terms of:

  1. Attainment of favorable FDA response to utilize a subcontractor for the manufacture of Ampligen;

  2. Continued development and study of Ampligen as an adjuvant potentially enhancing the effectiveness of vaccines against microbial infection;

  3. Success in the protection of company intellectual property;

  4. Continued development of Alferon LDO; and

  5. Maintaining the overall financial strength of the company and operations consistent with the board approved budget.

As a result of their review, the Compensation Committee has recommended and board of directors approved the award of bonus to Dr. William Carter, chairman & CEO ($182,772), Charles Bernhardt, CFO & Chief Accounting officer ($44,000), Dr. David Strayer, Medical director ($44,306) and Wayne Springate, V.P. of Operations ($33,000) and certain others.

Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders.

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.